Trade Monte Rosa Therapeutics Inc - GLUE CFD

Monte Rosa Therapeutics, Inc. Company profile

About Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. It develops a protein degradation platform, called QuEEN, that enables it to identify protein targets and molecular glue degrader (MGD), product candidates that are designed to eliminate therapeutically relevant proteins. It focuses on therapeutic targets backed by biological and genetic rationale discovering and developing novel precision medicines. It utilizes its Quantitative and Engineered Elimination of Neosubstrates (QuEEN), platform to design novel MGDs focused on delivering therapies to targets that have been considered undruggable or inadequately drugged in biological pathways across clinical indications in oncology and non-oncology, including immunology, inflammation, neurological and genetic diseases.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Monte Rosa Therapeutics Inc revenues was not reported. Net loss increased from $16.2M to $50.5M. Higher net loss reflects Research and development - Balancing val increase from $14.1M to $37.5M (expense), General and administrative - Balancing v increase from $1.9M to $8.7M (expense), Stock-based Compensation in General and increase from $79K to $1.8M (expense).